Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
674
datasets available to search
ShareScore release 0.9.0
Dataset results
674 results for “brain disease”
Data from: Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease
Open the record for dataset details and reuse information.
Ground truth labels for "BRAVE-NET: Fully Automated Arterial Brain Vessel Segmentation In Patients with Cerebrovascular Disease"
<p>Manual, voxel-wise segmentation ground truth labels for 20 healthy volunteers (4 from each age group) from the publicly available MIDAS data collection website under:<br> https://www.insight-journal.org/midas/community/view/21‌</p> <p> </p>
Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia
<p><span><span><span><span><span><span><span><span><span><span><span>MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, <span><span>has been</span></span> applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We <span><span>initiated a prospective, single-arm, non-randomized, proof-of-concept, safety and feasibility</span></span> phase I clinical trial <span><span>(NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD,</span></span> targeting the right parieto-occipito-temporal cortex where cortical pathology is foremost in this clinical state. <span><span>Changes in </span></span><span><span>β</span></span><span><span>-</span></span><span><span>amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements.</span></span> <span><span>Five patients were recruited from October 2018 until May 2019, and</span></span> received two <span><span>treatment</span></span> sessions separated by 2-3 weeks. <span><span>The results are set out in a descriptive manner.</span></span> Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. <span><span>We report BBB opening in the parieto-occipito-temporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening.</span></span> From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be <span><span>performed</span></span> repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.</span></span></span></span></span></span></span></span></span></span></span></p>
Data from: Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the HDHQ150/Q150 mouse model of Huntington's disease
A variety of mouse models have been developed that express mutant huntingtin (mHTT) leading to aggregates and inclusions that model the molecular pathology observed in Huntington's disease. Here we show that although homozygous HdhQ150 knock-in mice developed motor impairments (rotarod, locomotor activity, grip strength) by 36 weeks of age, cognitive dysfunction (swimming T maze, fear conditioning, odor discrimination, social interaction) was not evident by 94 weeks. Concomitant to behavioral assessments, T2-weighted MRI volume measurements indicated a slower striatal growth with a significant difference between wild type (WT) and HdhQ150 mice being present even at 15 weeks. Indeed, MRI indicated significant volumetric changes prior to the emergence of the "clinical horizon" of motor impairments at 36 weeks of age. A striatal decrease of 27% was observed over 94 weeks with cortex (12%) and hippocampus (21%) also indicating significant atrophy. A hypothesis-free analysis using tensor-based morphometry highlighted further regions undergoing atrophy by contrasting brain growth and regional neurodegeneration. Histology revealed the widespread presence of mHTT aggregates and cellular inclusions. However, there was little evidence of correlations between these outcome measures, potentially indicating that other factors are important in the causal cascade linking the molecular pathology to the emergence of behavioral impairments. In conclusion, the HdhQ150 mouse model replicates many aspects of the human condition, including an extended pre-manifest period prior to the emergence of motor impairments.
Data from: Blood-brain barrier impairment and hypoperfusion are linked in cerebral small vessel disease
Objective: To investigate the link between BBB permeability and CBF and the relation with white matter hyperintensities (WMHs) in cerebral small vessel disease (cSVD). Methods: Twenty-seven patients with cSVD received dynamic susceptibility contrast and dynamic contrast-enhanced MRI to determine CBF and BBB permeability (expressed as leakage rate and volume), respectively. Structural MR images were segmented into normal appearing white matter (NAWM) and WMHs, for which a perilesional zone was defined. In these regions, we investigated the BBB permeability, CBF, and their relation using Pearson correlation r. Results: We found a decrease in CBF of 2.2 mL/min/100g(p<0.01) and an increase in leakage volume of 0.7%(p<0.01) per mm closer to the WMHs in the perilesional zones. Lower CBF values correlated with higher leakage measures in the NAWM and WMHs (-0.53
Second wave, late-phase neuroinflammation in the brain of aged 5xFAD transgenic Alzheimer's disease model mice iden-tified using macrolaser light sheet microscopy imaging with tissue clearing
Open the record for dataset details and reuse information.
Parkinson's disease-related brain metabolic patterns and neurodegeneration in isolated REM sleep behavior disorder
<p><span><b>Objective</b>: To elucidate the role of Parkinson's disease (PD)-related brain metabolic patterns as a biomarker in isolated rapid-eye-movement sleep behavior disorder (iRBD) for future disease conversion.</span></p> <p><span><b>Method</b>: This is a prospective cohort study consisting of 30 iRBD patients, 25 de novo PD patients with a premorbid history of RBD, 21 long-standing PD patients on stable treatment and 24 healthy controls. iRBD group was longitudinally followed up. All participants underwent <sup>18</sup>F-Fluorodeoxyglucose (FDG) PET and were evaluated with olfaction, cognition, and the Movement disorders society-Unified PD Rating Scale (MDS-UPDRS) at baseline. From FDG-PET scans, we derived metabolic patterns from the long-standing PD group (PD-RP) and de novo PD group with RBD (dnPDRBD-RP). Subsequently, we calculated the PD-RP and dnPDRBD-RP scores in iRBD patients. We validated the metabolic patterns in each PD group and separate iRBD cohort (<i>n</i>=14).</span></p> <p><span><b>Result</b>: The two patterns significantly correlated with each other and were spatially overlapping yet distinct. The MDS-UPDRS motor scores significantly correlated with PD-RP (<i>p</i> = 0.013) but not with dnPDRBD-RP (<i>p</i> = 0.076). In contrast, dnPDRBD-RP correlated with olfaction in butanol threshold test (<i>p</i> = 0.018) in iRBD subjects, but PD-RP did not (<i>p</i> = 0.21). High dnPDRBD-RP in iRBD patients predicted future phenoconversion with all cut-off ranges from 1.5 to 3 standard deviations of the control value, whereas predictability of PD-RP was only significant in a partial range of cut-off.</span></p> <p><b>Conclusion:</b> The dnPDRBD-RP is an efficient neuroimaging biomarker that reflects prodromal features of PD and predicts phenoconversion in iRBD that can be applied individually.</p>
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
ClinicalTrials.gov study NCT00255086. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease
ClinicalTrials.gov study NCT02708485. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Combined Deep Brain Stimulation for Parkinson's Disease
ClinicalTrials.gov study NCT01485276. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
ClinicalTrials.gov study NCT00528801. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
ClinicalTrials.gov study NCT06797817. IPD Sharing: NO. Countries: 1. Publications: 0.
Exercise for Brain Health in the Fight Against Alzheimer's Disease
ClinicalTrials.gov study NCT03727360. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
ClinicalTrials.gov study NCT03981055. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones
ClinicalTrials.gov study NCT05778695. IPD Sharing: NO. Countries: 1. Publications: 0.
Research on the Brain Glymphatic System of Parkinson's Disease Patients Based on DTI Technology
ClinicalTrials.gov study NCT06858176. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study
ClinicalTrials.gov study NCT06391853. IPD Sharing: YES. Countries: 0. Publications: 16.
Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
ClinicalTrials.gov study NCT03204526. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
ClinicalTrials.gov study NCT04057807. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Asleep MRI-guided Versus Awake Microelectrode Recording Guided Deep Brain Stimulation in Parkinson's Disease: A Comparative Effectiveness Trial
ClinicalTrials.gov study NCT05453331. IPD Sharing: NO. Countries: 0. Publications: 34.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.